lifestyle.capitolhilltimes.com

Author: BioNxt Solutions Inc.

BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)

April 14, 2026
BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries

April 7, 2026
BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy

March 30, 2026
BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe

March 17, 2026
BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis

February 17, 2026
BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery

February 11, 2026
BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion

January 26, 2026
BioNxt Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery for the Treatment Multiple Sclerosis (MS)

January 21, 2026
BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF

January 19, 2026
Over 40% of Adults Struggle to Swallow Pills – BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies

December 17, 2025